Insider Selling: Penumbra Inc (PEN) CEO Sells 8,000 Shares of Stock
Penumbra Inc (NYSE:PEN) CEO Adam Elsesser sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $125.30, for a total value of $1,002,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Adam Elsesser also recently made the following trade(s):
- On Thursday, April 11th, Adam Elsesser sold 8,000 shares of Penumbra stock. The shares were sold at an average price of $141.58, for a total value of $1,132,640.00.
- On Monday, March 11th, Adam Elsesser sold 8,000 shares of Penumbra stock. The shares were sold at an average price of $139.86, for a total value of $1,118,880.00.
Penumbra stock traded up $1.24 during mid-day trading on Wednesday, hitting $135.03. 228,830 shares of the company were exchanged, compared to its average volume of 417,545. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.34 and a current ratio of 6.10. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of 264.76, a PEG ratio of 6.56 and a beta of 0.71. Penumbra Inc has a 12-month low of $110.84 and a 12-month high of $167.35.
A number of institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of Penumbra by 2.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 125,815 shares of the company’s stock valued at $18,835,000 after purchasing an additional 2,774 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Penumbra by 15.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 49,924 shares of the company’s stock worth $7,473,000 after purchasing an additional 6,575 shares during the period. Teachers Advisors LLC increased its holdings in shares of Penumbra by 2.1% in the 3rd quarter. Teachers Advisors LLC now owns 41,994 shares of the company’s stock valued at $6,287,000 after acquiring an additional 883 shares during the last quarter. Morgan Stanley increased its holdings in shares of Penumbra by 3.1% in the 3rd quarter. Morgan Stanley now owns 732,897 shares of the company’s stock valued at $109,714,000 after acquiring an additional 21,910 shares during the last quarter. Finally, Vanguard Group Inc boosted its position in shares of Penumbra by 2.7% in the 3rd quarter. Vanguard Group Inc now owns 2,646,066 shares of the company’s stock valued at $396,116,000 after purchasing an additional 68,479 shares during the period. 81.50% of the stock is owned by institutional investors.
Several equities analysts recently weighed in on PEN shares. Canaccord Genuity raised their price objective on Penumbra from $138.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, January 30th. Zacks Investment Research raised Penumbra from a “hold” rating to a “buy” rating and set a $149.00 price objective for the company in a research note on Saturday. HC Wainwright reaffirmed a “buy” rating on shares of Penumbra in a research note on Wednesday, April 17th. Finally, ValuEngine raised Penumbra from a “hold” rating to a “buy” rating in a research note on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Penumbra currently has an average rating of “Buy” and a consensus price target of $141.83.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Recommended Story: Conference Calls
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.